Aligos Therapeutics ALGS Income Statement (2019-2026)

NASDAQ ALGS
$2.10 +0.12 (+6.06%)
At close: Nov 13, 2026 · 4:00 PM EST
Reported Financials

Aligos Therapeutics Quarterly Income Statement

Periods 29 quarters
Latest Sep 2026

Aligos Therapeutics reported revenue of $2.83M and net income of -$21.86M for the quarter ended Sep 2026, up 281.9% year over year. This income statement covers 29 quarters of results from Sep 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
0.37M2.57M3.69M4.11M3.54M2.58M4.29M2.15M2.01M0.69M1.06M1.25M0.61M0.31M0.97M0.74M0.17M2.83M2.83M
Operating items
Research & DevelopmentR&D
28.60M31.68M16.51M17.79M19.10M18.14M16.78M15.87M22.26M16.37M21.10M16.77M16.03M14.50M13.98M23.94M17.04M23.35M24.05M18.89M
Selling, General & AdministrativeSG&A
9.72M6.45M7.58M5.26M7.12M8.51M9.25M6.44M6.42M6.67M6.38M4.63M5.16M5.05M5.56M5.17M4.95M6.41M5.62M5.87M
Other Operating ExpensesOther Opex
0.18M-0.01M0.52M0.28M0.85M1.00M1.11M1.06M0.24M1.58M1.23M1.07M0.57M0.88M1.21M1.09M0.75M0.81M0.22M0.17M
Operating ExpensesOpex
38.32M38.13M24.09M23.05M26.22M26.64M26.03M22.31M28.68M23.03M27.48M21.40M21.19M19.55M19.53M29.10M21.98M29.76M29.67M24.76M
Operating IncomeOp. Inc
-37.95M-35.56M-20.39M-18.95M-22.68M-23.92M-19.14M-19.07M-26.00M-22.05M-26.41M-20.13M-20.56M-19.24M-18.57M-28.36M-21.81M-26.93M-1.89M-21.89M
Non-operating items
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
-0.25M-0.15M0.11M0.24M0.10M0.00M-0.07M0.02M0.08M-0.02M0.00M-0.03M0.04M0.02M-0.03M0.00M
Other Non Operating IncomeOther Non Op Inc.
-0.25M-0.15M-0.07M0.00M-0.03M-0.03M0.00M
Net income details
EBIT
-37.95M-35.56M-20.39M-18.95M-22.68M-23.92M-19.14M-19.07M-26.00M-22.05M-26.41M-20.13M-20.56M-19.24M-18.57M-28.36M-21.81M-26.93M-1.89M-21.89M
EBT
-37.77M-35.56M-19.88M-18.66M-21.84M-22.92M-18.03M-18.01M-27.92M-34.84M5.25M-19.17M-82.12M43.13M-15.68M-31.48M-19.85M-22.72M1.31M-21.53M
Tax ProvisionsTaxes
-0.06M0.05M0.05M-0.04M0.05M0.04M0.76M0.03M-0.03M0.02M0.19M0.09M0.03M0.04M0.19M0.06M0.03M0.32M2.81M0.33M
Income After Tax
-37.71M-35.62M-19.92M-18.62M-21.89M-22.96M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M-1.50M-21.86M
Income from Continuing OperationsIncome (Continuing)
-37.71M-35.62M-19.92M-18.62M-21.89M-22.96M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M-1.50M-21.86M
Consolidated Net IncomeConsol Net Inc.
-37.01M-35.86M-20.08M-18.51M-21.64M-22.86M-18.79M-18.04M-27.84M-34.93M5.08M-19.18M-82.28M43.08M-15.89M-31.50M-19.87M-23.07M-1.51M-21.86M
Net Income Attributable to Noncontrolling InterestsNCI Net Income
-18.79M41.75M-34.93M5.08M0.08M43.08M
Net Income - Minority
-43.09M15.86M23.04M1.50M
Income towards Parent CompanyParent Net Inc
-37.71M-35.62M-19.92M-18.62M-21.89M-22.96M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M-1.50M-21.86M
Net Income towards Common StockholdersNet Income
-37.71M-35.62M-19.92M-18.62M-21.89M-22.96M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-19.88M-23.04M-1.50M-21.86M
Additional items
EPS (Basic)
-0.95-0.84-0.47-0.44-0.51-0.53-0.43-0.41-0.43-0.220.03-3.07-13.115.12-1.53-3.04-2.01-2.21-0.14-2.09
EPS (Diluted)
-0.89-0.84-0.47-0.44-0.51-0.53-0.43-0.41-0.43-5.580.81-3.07-13.114.95-1.53-3.04-2.01-2.21-0.14-2.09
Shares Outstanding
39.86M42.51M42.67M42.76M42.70M42.91M43.22M43.50M64.26M156.15M156.44M6.27M6.26M8.41M10.35M10.37M9.88M10.40M10.43M10.46M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
42.40M42.51M42.67M42.76M42.70M42.91M43.22M43.50M64.26M6.25M6.27M6.27M6.26M8.71M10.35M10.37M9.88M10.40M10.43M10.46M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
42.69M42.70M42.81M42.82M42.92M42.94M43.50M43.50M64.26M156.15M156.44M6.27M6.26M8.41M10.35M10.37M9.88M10.40M10.43M10.46M
EBITDA
-37.23M-34.86M-19.79M-18.45M-22.18M-23.42M-18.74M-18.77M-25.60M-21.75M-26.11M-19.83M-20.34M-19.04M-18.27M-28.16M-21.58M-26.58M-1.59M-21.59M
Tax Rate
3.60%0.10%215.07%

Aligos Therapeutics Income Statement API

Pull Aligos Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ALGS&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY